[{"id":"ae37ad26-112d-406e-b4ec-b9bd80c911c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05292664","created_at":"2022-03-23T13:53:35.750Z","updated_at":"2025-02-25T14:08:44.222Z","phase":"Phase 1","brief_title":"Venetoclax Basket Trial for High Risk Hematologic Malignancies","source_id_and_acronym":"NCT05292664","lead_sponsor":"Andrew E. Place, MD","biomarkers":" FLT3 • ABL1 • BCR • BCL2 • KMT2A • IKZF1","pipe":" | ","alterations":" KMT2A rearrangement • ABL1 fusion","tags":["FLT3 • ABL1 • BCR • BCL2 • KMT2A • IKZF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement • ABL1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • doxorubicin hydrochloride • azacitidine • vincristine • leucovorin calcium • Asparlas (calaspargase pegol-mknl) • dexrazoxane"],"overall_status":"Recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 03/29/2023","start_date":" 03/29/2023","primary_txt":" Primary completion: 07/02/2026","primary_completion_date":" 07/02/2026","study_txt":" Completion: 07/02/2028","study_completion_date":" 07/02/2028","last_update_posted":"2025-02-17"},{"id":"357b4d1c-0cfa-4162-a300-61812b45530e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05602194","created_at":"2022-11-02T14:56:42.944Z","updated_at":"2025-02-25T15:20:06.675Z","phase":"Phase 3","brief_title":"Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma","source_id_and_acronym":"NCT05602194","lead_sponsor":"Children's Oncology Group","biomarkers":" CRLF2 • PNPLA3 • SOD2","pipe":"","alterations":" ","tags":["CRLF2 • PNPLA3 • SOD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Oncaspar liquid (pegaspargase) • Asparlas (calaspargase pegol-mknl)"],"overall_status":"Recruiting","enrollment":" Enrollment 440","initiation":"Initiation: 08/24/2023","start_date":" 08/24/2023","primary_txt":" Primary completion: 06/30/2028","primary_completion_date":" 06/30/2028","study_txt":" Completion: 12/30/2028","study_completion_date":" 12/30/2028","last_update_posted":"2025-02-12"},{"id":"f63cdb8b-80b6-404d-814f-9d31ad0e7012","acronym":"2087GCCC","url":"https://clinicaltrials.gov/study/NCT04666649","created_at":"2021-01-19T20:43:47.273Z","updated_at":"2024-07-02T16:35:11.039Z","phase":"Phase 1","brief_title":"Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)","source_id_and_acronym":"NCT04666649 - 2087GCCC","lead_sponsor":"University of Maryland, Baltimore","biomarkers":" TP53 • FLT3 • IDH1","pipe":" | ","alterations":" TP53 mutation • IDH2 mutation","tags":["TP53 • FLT3 • IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Asparec (PEGylated recombinant Erwinia chrysantemi-derived L-asparaginase)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 03/10/2021","start_date":" 03/10/2021","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-04-08"},{"id":"92f3f7c6-e282-4c02-a649-a3d88aca09fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04953780","created_at":"2024-03-18T13:21:29.779Z","updated_at":"2024-07-02T16:35:14.325Z","phase":"Phase 1","brief_title":"2157GCCC:Phase 1 of Calaspargase Pegol-mknl w/ Cytarabine and Idarubicin in Newly Dx AML","source_id_and_acronym":"NCT04953780","lead_sponsor":"University of Maryland, Baltimore","biomarkers":" MCL1 • BCL2L1","pipe":" | ","alterations":" BCL2 expression","tags":["MCL1 • BCL2L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride • Asparlas (calaspargase pegol-mknl)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 09/27/2021","start_date":" 09/27/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-18"}]